The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 38454565.
- Also identified by DOI 10.1093/bjd/ljae096 and PMC identifier 11099981.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Psoriasis is a common inflammatory skin condition affecting approximately 2–3% of people worldwide. Methotrexate (MTX) is a cheap and effective drug that is often recommended as the first-choice systemic agent for psoriasis. Around 40–50% of patients achieve a good response; however, mechanisms of nonresponse are poorly understood. It is not known whether biochemical MTX adherence in patients with psoriasis is suboptimal and requires intervention. Our aim was to audit biochemical MTX adherence using a sensitive liquid chromatography–tandem mass spectrometry in patients prescribed oral MTX for the treatment of psoriasis at our tertiary dermatology centre. Ethical approval for this audit was not required as confirmed by the Health Research Authority.
Medical subject headings
- Psoriasis
- Methotrexate
- Dermatologic Agents
- Drug Monitoring